Literature DB >> 32733388

Working Hypothesis for Glucose Metabolism and SARS-CoV-2 Replication: Interplay Between the Hexosamine Pathway and Interferon RF5 Triggering Hyperinflammation. Role of BCG Vaccine?

Hugo A Laviada-Molina1, Irene Leal-Berumen2, Ernesto Rodriguez-Ayala3, Raul A Bastarrachea4.   

Abstract

Entities:  

Keywords:  BCG; HB pathway; IRF5; SARS-CoV-2; cytokine storm

Mesh:

Substances:

Year:  2020        PMID: 32733388      PMCID: PMC7358362          DOI: 10.3389/fendo.2020.00514

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


× No keyword cloud information.

Introduction

Respiratory epithelial cells, dendritic cells (DCs) and macrophages (1) secrete low levels of the antiviral factor interferons (IFNs) (2) and high levels of proinflammatory cytokines such as tumor necrosis factor alpha (TNFα), IL-6, and IL-1β, IP-10, MCP-3, characterizing the pathophysiologic features of severe acute respiratory syndrome (ARDS) induced by SARS-CoV-2 infection (3). Researchers hypothesized that after COVID-19 infects human cells, the virus utilizes an excess of glucose for a fast viral replication from the hexosamine biosynthetic pathway (HBP) hijacking substrates from the metabolic environment. This process induces overexpression of interferon IRF5, leading to a massive inflammatory gene overexpression, endoplasmic reticulum (ER) stress, and cytokine dysregulation profile. This deleterious cytokine overproduction is referred to as the cytokine storm (Figure 1). It leads to an increased risk of vascular hyperpermeability, multiorgan failure, and hyperinflammation (4, 5). Little is known about the molecular immunometabolic mechanism that triggers the uncontrolled surge in cytokine secretion and the cellular regulation of the hyperinflammatory cascade intertwined with the COVID-19 viral replication.
Figure 1

Work in progress hypothesis for the hyperinflammatory HBP-GlcNAc-OGT–IRF5-interferon-SARS-CoV-2 pathway leading to the cytokine storm.

Work in progress hypothesis for the hyperinflammatory HBP-GlcNAc-OGTIRF5-interferon-SARS-CoV-2 pathway leading to the cytokine storm.

Chronic Low-Grade Subclinical Inflammation: Underlying Mechanism Enhacing the COVID-19 Cytokine Storm in the Presence of Dysglycemia

Older people, immunocompromised, diabetics and/or hypertensives are more likely to develop the cytokine storm. Dysglycemia is characterized by glucose intolerance and insulin resistance (6, 7). Additionally, aberrant expression of proinflammatory cytokines adds to the toxic milieu of dysglycemia (8). These immunometabolic disturbances also include hyperglycemic posprandial peaks perhaps exacerbating the excess of proinflammatory cytokines in COVID-19 (9). However, a subgroup of symptom-free non-diabetic, overweight individuals with mild body fat accumulation and insulin resistance (IR) and/or prediabetes (10), and a second subgroup of symptom-free normal weight metabolically unhealthy subjects have a 3-fold higher risk of all-cause mortality and/or cardiovascular events (11). These two subgroups are also at high-risk to develop the cytokine storm. They have in common a chronic systemic low-grade subclinical proinflammatory (CLGSPI) state (12) characterized by adipose tissue dysfunction (ATdys) (13) and macrophage polarization in adipose tissue, low adiponectin levels, cytokines and circulating inflammatory C-reactive protein (CRP) that perpetuates this deleterious CLGSPI and promotes insulin resistance (14). These subgroups of individuals with underlying but undetected postprandial dysglycemia, CLGSPI and ATdys present a proinflamatory pathology that is highly underestimated and rarely diagnosed among symptom-free individuals in the practice setting. This undetected deleterious chronic low-grade proinflamatory scenario perhaps together with postprandial glucose excursions is proposed here as the underlying mechanism enhancing the hyperinflammatory state in these infected symptom-free subjects with COVID-19 triggering multi-organ failure.

Glucose Metabolism, the Hexosamine Pathway, IRF5, SARS-CoV-2 Replication and Cytokine Storm

After glucose uptake, in addition to glycolysis, glucose metabolism generates UDP-GlcNAc (uridinediphosphate- β-D-N- acetylglucosamine) via the HBP pathway. The HBP links cellular signaling and gene expression to glucose, amino acid, fatty acid and nucleotide metabolism (15, 16). It is regulated by the enzymes OGT (O-GlcNAc transferase) and OGA (O-GlcNAcase), that catalyze the addition and removal of GlcNAc on proteins (17). UDP-GlcNAc is a substrate for N-glycosylation, a process important for protein folding within the ER (18, 19) (Figure 1). The HBP- O-GlcNAc pathway has also been characterized as a major contributor to the deleterious effects of dysglycemic states, also influencing cellular proliferation. These dysglycemic states, mainly overt hyperglycemia, have a significant contribution in oncogenesis, tumor progression and fatal outcomes, indicating that there is a link between glucose metabolic disorders and tumor growth of cancer cells (20, 21). Similar biological characteristics are found in viruses. They rearrange the metabolic environment in the infected cells to facilitate virus replication. Indeed, virus-infected cells increase glycolytic metabolism to secure precursors for an increased biosynthesis (lipids, nucleotides) to optimize virus production and replication (22, 23). Nuclear factor-kB (NF-kB) and IKK are associated with metabolic disorders (24), also playing important roles in inflammatory and immune responses (25). O-GlcNAcylation regulates direct modification of transcription factors such as NF-kB (26, 27). Cells use the HBP and OGT to potentiate gene expression through NF-kB as a glucose-responsive transcription factor in response to TNFα (28) (Figure 1). The interferon-regulatory factor (IRF) family plays a critical role in regulating the immune system, the innate immune response and the development of immune cells. IRFs are primarily implicated in antiviral responses and interferon production. IRFs also have key functions in the regulation of metabolism (29). Among the IRF family members, Interferon Regulatory Factor 5 (IRF5) is a key player in inflammation (30). IRF5 mediates induction of proinflammatory cytokines such as interleukin-6 (IL-6), IL-12, IL-23 and TNFα, is involved in the recruitment of inflammatory genes with NF-kB, and in determining the inflammatory macrophage phenotype (31). Host protection by IRF5 is achieved through its role in the nucleus triggering transcriptional activation of proinflammatory type I interferon (IFN), promotion of apoptosis-related genes and regulation of cytokines involved in cell survival, growth, proliferation, and differentiation (32). ER stress can result in the accumulation of unfolded proteins, triggering the unfolded protein response (UPR), an adaptive reaction that reduces unfolded protein load to maintain cell viability and function, capable of sensing dangerous aggressions and reverse them by influencing the immune response through interferon production (33). Cells infected with viruses induce ER stress and stimulate strong interferon responses (34). Viral replication is inhibited by an interferon-regulated gene product, the double-stranded RNA-dependent protein kinase (PKR). Interferon employs its antiviral properties by activating PKR, thereby inhibiting viral replication. ER stress is a critical component in the response against viral infections. A prolonged ER stress triggers apoptosis. Therefore, the task of a virus is to overcome the interferon response involving PKR and manipulate the unfolded protein response (UPR) to facilitate viral replication and cause disease (34). A recent study demonstrated that influenza A virus (IAV) was able to induce a cytokine storm via interferon (IFN) regulatory factor−5 (IRF5) through glucose metabolism utilization and an increase in O-GlcNAc signaling, demonstrating that the HBP– O-GlcNAc signaling pathway in influenza A virus (IAV) promoted a massive inflammatory cytokine overexpression (35). SARS-CoV-2 infects human cells also leading perhaps to an excess of glucose utilization (16). Indeed, the HBP pathway activated in IAV infections generates UDP-N-Acetylglucosamine (UDP-GlcNAc), substrate for the key enzyme for protein O-GlcNAcylation O-GlcNAc transferase (OGT) (15). This enzyme has a strong binding affinity to signaling protein interferon regulatory factor 5 (IRF5) (35). Viral infections such as IAV and SARS-CoV-2 may create an excess in IRF5, leading to ER stress and rapid ubiquitination, triggering an excess of cytokine overproduction, hyperinflammation and multiorgan failure (36) (Figure 1). Another study identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates mitochondrial antiviral signaling protein (MAVS) function (37) and highlighted the importance of glucose metabolism in antiviral innate immunity (38).

Could BCG Avoid the Hijacking of the HBP-O-GlcNAc-OGT Complex by SARS-CoV-2 to Restore Immunity and Balance Cellular Metabolism?

BCG-treated type 1 diabetes (T1D) individuals showed a durable lowering of HbA1c and glucose (39). BCG appears to switch the immune system of T1Ds from high oxidative phosphorylation to augmented glycolysis, a systemic metabolic shift that allows cells to consume large amounts of glucose to safely lower hyperglycemia (39, 40). The authors were able to reset the immune system to a state of increased glycolysis at the cellular level through turning on T regulatory (Treg) cells. The BCG effect on immune metabolism apparently accelerated glucose utilization through increased glycolysis, a high-glucose-transport process through the pentose phosphate shunt, instead of using the Krebs cycle for oxidative phosphorylation (40). The immune effects of BCG in T1D relates to the autoimmune environment comprising too few suppressive T regulatory (Treg) cells and too many cytotoxic T lymphocytes (CTLs). With BCG treatment, Treg cell expansion and augmented function occurred, and CTLs died thus restoring the immune balance toward normal at the autoimmune site (41). Figure 1 shows multiple potential molecular targets for BCG activity in COVID-19 infected individuals. Based on the immunomodulatory roles of mycobacteria, an effect from BCG vaccination on the spread and severity of COVID-19 dissemination in different countries could have occurred (42). Researchers classified countries into 2 groups according to presence or absence of BCG vaccination in their routine vaccine schedules and obtained confirmed numbers of COVID-19 cases and deaths from the World Health Organization (WHO). They found that the mean of cases per population ratio was statistically significantly lower in BCG vaccinated countries when compared to BCG-non-vaccinated countries, also finding that both the mean deaths per population and the deaths per cases ratio were significantly lower in BCG-vaccinated countries. They concluded that the cessation of BCG vaccination in several countries within the last few decades should be reanalyzed given its impact regarding the immune response to hypothetical viral pandemics we might face in the future on BCG-non-vaccinated young individuals (42–44). Vaccination with BCG triggers a memory-like response in innate immune cells known as “trained immunity” associated to an epigenetic reprogramming mechanism in both humans and mice (45). However, some authors advice caution when interpreting data on Covid-19 incidence and BCG vaccination. Further research is definitively needed to prove that the BCG vaccine confers protection against COVID-19. Indeed, the current state of knowledge does not provide sufficient evidence (46). A trial for BCG vaccination to reduce the impact of COVID-19 in Australian healthcare workers (BRACE) has been set to investigate whether BCG vaccination protects against COVID-19 (mcri.edu.au/BRACE).

Discussion

As depicted in Figure 1, we speculate as a work in progress hypothesis that after SARS-CoV-2 have entered human cells through the ACE 2 receptor, its first priority, similar to IAV, would be to enhance the HBP pathway to secure excessive glucose consumption and substrates for rapid replication. This abnormal HBP hyperactivity would lead to an excess of the OGT enzyme that would consequently trigger large amounts of IRF5 interferon. IRF5 and OGT will then coordinate efforts to exacerbate the IKK-NF-kB proinflamatory pathway triggering in the nucleus a massive inflammatory cytokine gene overexpression profile and a deleterious ER stress that ultimately result in hyperinflammation, a cytokine storm and multiorgan failure. The detrimental consequences are not hard to imagine when this life-threatening hyperinflammatory HBP-GlcNAc-OGTIRF5-interferon-SARS-CoV-2 pathway from the COVID-19 pandemic meets with CLGSPI found in common, complex highly prevalent pandemics such as obesity and diabetes, also found in not so old individuals with symptom-free adipose tissue dysfunction, insulin resistance, the metabolic syndrome and/or prediabetes (13, 47). These four groups of individuals present postprandial hyperglycemia which is one of the earliest abnormalities of glucose homeostasis associated with dysglycemic states (48). A recent publication highlighted the significance of angiotensin converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4), and their dual physiologic effects as transducers of metabolic signals regulating inflammation, cardiovascular physiology, and glucose homeostasis (49). This opens the door to consider glucose-lowering agents such as the DPP4 inhibitors as tools to intervene in the interaction of COVD-19, dysglycemic states and the HBP-GlcNAc-OGTIRF5-interferon pathway, keeping in mind that DPP-4 inhibitors are not indicated in T1D individuals (50). In summary, the HBP-GlcNAc-OGTIRF5-interferon-SARS-CoV-2 pathway may have important implications regarding direct or indirect specific molecular targets for BCG activity (Figure 1). Importantly, dietary specific indications for low glycemic index diets (51, 52) instead of general dietary recommendations for COVID-19 infected individuals and/or at risk of infection may seem appropriate. This is supported by the hypothetical association between the large postprandial glucose peaks after daily meals, the HBP-GlcNAc-OGTIRF5-interferon pathway and subjects with dysglycemia, adipose tissue dysfunction and low-grade subclinical inflammation at risk for severe COVID-19 infection.

Author Contributions

RB and HL-M wrote the manuscript. IL-B edited and revised the manuscript. ER-A revised the final version. All authors have read and approved the final manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  51 in total

Review 1.  Cytokine storm and sepsis disease pathogenesis.

Authors:  Benjamin G Chousterman; Filip K Swirski; Georg F Weber
Journal:  Semin Immunopathol       Date:  2017-05-29       Impact factor: 9.623

Review 2.  Macrophage functions in lean and obese adipose tissue.

Authors:  Dylan Thomas; Caroline Apovian
Journal:  Metabolism       Date:  2017-04-18       Impact factor: 8.694

3.  OGT-mediated O-GlcNAcylation promotes NF-κB activation and inflammation in acute pancreatitis.

Authors:  Dongmei Zhang; Yongxia Cai; Minmin Chen; Lili Gao; Yanbo Shen; Zhongwei Huang
Journal:  Inflamm Res       Date:  2015-09-25       Impact factor: 4.575

Review 4.  Atherogenicity of postprandial hyperglycemia and lipotoxicity.

Authors:  Antonio Ceriello; Stefano Genovese
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

5.  Considering BCG vaccination to reduce the impact of COVID-19.

Authors:  Nigel Curtis; Annie Sparrow; Tedros A Ghebreyesus; Mihai G Netea
Journal:  Lancet       Date:  2020-04-30       Impact factor: 79.321

Review 6.  Hyperglycemia-Induced Aberrant Cell Proliferation; A Metabolic Challenge Mediated by Protein O-GlcNAc Modification.

Authors:  Tamás Nagy; Viktória Fisi; Dorottya Frank; Emese Kátai; Zsófia Nagy; Attila Miseta
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

7.  O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5.

Authors:  Qiming Wang; Peining Fang; Rui He; Mengqi Li; Haisheng Yu; Li Zhou; Yu Yi; Fubing Wang; Yuan Rong; Yi Zhang; Aidong Chen; Nanfang Peng; Yong Lin; Mengji Lu; Ying Zhu; Guoping Peng; Liqun Rao; Shi Liu
Journal:  Sci Adv       Date:  2020-04-15       Impact factor: 14.136

8.  Towards precision medicine: defining and characterizing adipose tissue dysfunction to identify early immunometabolic risk in symptom-free adults from the GEMM family study.

Authors:  Ernesto Rodriguez-Ayala; Esther C Gallegos-Cabrales; Laura Gonzalez-Lopez; Hugo A Laviada-Molina; Rocio A Salinas-Osornio; Edna J Nava-Gonzalez; Irene Leal-Berumen; Claudia Escudero-Lourdes; Fabiola Escalante-Araiza; Fatima A Buenfil-Rello; Vanessa-Giselle Peschard; Antonio Laviada-Nagel; Eliud Silva; Rosa A Veloz-Garza; Angelica Martinez-Hernandez; Francisco M Barajas-Olmos; Fernanda Molina-Segui; Lucia Gonzalez-Ramirez; Rebeca Espadas-Olivera; Ricardo Lopez-Muñoz; Ruy D Arjona-Villicaña; Victor M Hernandez-Escalante; Martha E Rodriguez-Arellano; Janeth F Gaytan-Saucedo; Zoila Vaquera; Monica Acebo-Martinez; Judith Cornejo-Barrera; Jancy Andrea Huertas-Quintero; Juan Carlos Castillo-Pineda; Areli Murillo-Ramirez; Sara P Diaz-Tena; Benigno Figueroa-Nuñez; Melesio E Valencia-Rendon; Rafael Garzon-Zamora; Juan Manuel Viveros-Paredes; José Ángeles-Chimal; Jesús Santa-Olalla Tapia; José M Remes-Troche; Salvador B Valdovinos-Chavez; Eira E Huerta-Avila; Juan Carlos Lopez-Alvarenga; Anthony G Comuzzie; Karin Haack; Xianlin Han; Lorena Orozco; Susan Weintraub; Jack W Kent; Shelley A Cole; Raul A Bastarrachea
Journal:  Adipocyte       Date:  2020-12       Impact factor: 4.534

9.  NF-κB signaling in inflammation.

Authors:  Ting Liu; Lingyun Zhang; Donghyun Joo; Shao-Cong Sun
Journal:  Signal Transduct Target Ther       Date:  2017-07-14

Review 10.  Regulation of Cytokine Production by the Unfolded Protein Response; Implications for Infection and Autoimmunity.

Authors:  Judith A Smith
Journal:  Front Immunol       Date:  2018-03-05       Impact factor: 7.561

View more
  8 in total

1.  Diagnosis and prognosis of COVID-19 employing analysis of patients' plasma and serum via LC-MS and machine learning.

Authors:  Alexandre de Fátima Cobre; Monica Surek; Dile Pontarolo Stremel; Mariana Millan Fachi; Helena Hiemisch Lobo Borba; Fernanda Stumpf Tonin; Roberto Pontarolo
Journal:  Comput Biol Med       Date:  2022-05-21       Impact factor: 6.698

Review 2.  Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus.

Authors:  Yu-Huang Liao; Jing-Quan Zheng; Cai-Mei Zheng; Kuo-Cheng Lu; You-Chen Chao
Journal:  J Clin Med       Date:  2020-12-07       Impact factor: 4.241

Review 3.  The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism.

Authors:  Abdolkarim Mahrooz; Giovanna Muscogiuri; Raffaella Buzzetti; Ernesto Maddaloni
Journal:  Endocrine       Date:  2021-04-22       Impact factor: 3.633

Review 4.  Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19.

Authors:  Nicholas Stoy
Journal:  Front Immunol       Date:  2021-04-07       Impact factor: 7.561

5.  Glutamine-Driven Metabolic Adaptation to COVID-19 Infection.

Authors:  Hüseyin Aydın; Yusuf Kenan Tekin; İlhan Korkmaz; Gülaçan Tekin; Sefa Yurtbay; Sami Keleş; Nezih Hekim
Journal:  Indian J Clin Biochem       Date:  2022-04-08

Review 6.  Mechanisms of COVID-19 pathogenesis in diabetes.

Authors:  Chandrakala Aluganti Narasimhulu; Dinender K Singla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-07-01       Impact factor: 5.125

7.  Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes.

Authors:  Fawaz Alzaid; Jean-Baptiste Julla; Marc Diedisheim; Charline Potier; Louis Potier; Gilberto Velho; Bénédicte Gaborit; Philippe Manivet; Stéphane Germain; Tiphaine Vidal-Trecan; Ronan Roussel; Jean-Pierre Riveline; Elise Dalmas; Nicolas Venteclef; Jean-François Gautier
Journal:  EMBO Mol Med       Date:  2020-09-11       Impact factor: 12.137

8.  Repetitive Intermittent Hyperglycemia Drives the M1 Polarization and Inflammatory Responses in THP-1 Macrophages Through the Mechanism Involving the TLR4-IRF5 Pathway.

Authors:  Fatema Al-Rashed; Sardar Sindhu; Hossein Arefanian; Ashraf Al Madhoun; Shihab Kochumon; Reeby Thomas; Sarah Al-Kandari; Abdulwahab Alghaith; Texy Jacob; Fahd Al-Mulla; Rasheed Ahmad
Journal:  Cells       Date:  2020-08-12       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.